Coast to Coast
We were thrilled this year to announce that Mediso USA reached a major milestone with the establishment of its tenth preclinical nanoScan imaging system in North America. We are looking back this holiday season with so much appreciation for all of you in making this possible.
It was a great honor to have our first site in North America designated as a Center of Excellence for Preclinical Imaging. Many thanks to the Center for Quantitative Cancer Imaging team at the Huntsman Cancer Institute (HCI), part of the University of Utah Health Care system in Salt Lake City. We look forward to continuing our partnership into the New Year.
State of the Art
With its nanoScan PET/MRI(3T) installations dotting the globe, Mediso accepts only the best in imaging performance. As such, the nanoScan PET/MRI(3T) system features a 3T translational MR field strength combined with exceptional PET performance in a compact cryogen-free and low fringe field design, guarantying low running costs and an easy-to-use workflow.
Up and Coming
Our team is also looking forward to a major advance on our horizon. We are proud to say that 2016 will feature our first MultiScan LFER 150 PET/CT installation in the U.S. The large bore in-vivo imaging system is tuned for translational research, capable of whole-body NHP imaging. Time to plan those F220 replacements!
SfN's 45th annual meeting is the premier venue for neuroscientists to present emerging science, learn from experts, forge collaborations with peers, explore new tools and technologies, and advance careers. Neuroscience 2015 will take place October 17-21 at McCormick Place in Chicago.
Please visit us at Booth #343 where we look forward to showing you the nanoScan PET/MRI(3T), the ultimate translational imaging tool for neuroscience. You can navigate the whole floor plan at My Neuroscience Marketplace.
We're looking forward to seeing you in Chicago!
ISMRM 2015 was a nice experience, our first time as an exhibitor - introduced the nanoScan PET/MRI 3T. Compact and charming as all nanoScan product - sharing the Nucline acquisition framework, MultiCell animal handling system with other nanoScan systems. We're leaving Toronto, ON to Baltimore, MD for the SNMMI 2015 Annual Conference: http://www.medisousa.com/events/mediso-usa-at-snmmi-2015-annual-meeting.
See you at our Booth #135!
The submission deadline is May 29, 2015.
The objective of these programs is to make available to institutions expensive, commercially available research systems that cost at least $50,000 (SIG Program) or at least $600,000 (HEI Program). The maximum award is $600,000 for the SIG program and $2,000,000 for the HEI Program.
The instruments can only be justified on a shared-use basis and that are needed for NIH-supported projects in basic, translational or clinical areas of biomedical/behavioral research (description from nih.gov). The SIG Program provides funds to purchase or upgrade a single item of expensive, specialized, commercially available instrument or an integrated instrumentation system to be used for research purposes only. To promote cost effectiveness, to encourage optimal sharing among individual investigators, research groups and departments, and to foster a collaborative multidisciplinary environment, the instrument should be integrated in a centralized core facility, whenever possible.
We, Mediso USA provide support to submit a successful instrumentation grant and we are committed to supporting you throughout the grant process. Please contact us for more details.
- Shared Instrumentation Grant (SIG) Program (S10): http://grants.nih.gov/grants/guide/pa-files/PAR-15-088.html
- High-End Instrumentation (HEI) Grant Program (S10): http://grants.nih.gov/grants/guide/pa-files/PAR-15-118.html
The annual meeting of the Society for Neuroscience is ongoing with the exhibition starting tomorrow. on Sunday. We're looking forward to seeing you in Washington DC.
Please visit us at booth #711 where we look forward to showing you what’s new in the world of preclinical and translational molecular imaging.
Related to Neuroscience, especially Imaging: The list of recommended publications page was expanded again before the event: 'Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring' from Piel at al published in the August 2014 issue of the Journal of Medicinal Chemistry. The article summarizes how PET can be be a valuable tool in CNS drug research and also features our nanoScan PET/MRI.
Right now, we especially offer two of our products to the interest of the Neuroscience 2014 participants for neurology research: the nanoScan PET/MRI and the MultiScan LFER 150 PET/CT.
We hope to see you on the exhibition floor.
October 18-22, Gothenburg, Sweden
Visit Mediso at booth #171 - our booth is conveniently located next to the biggest cafeteria on the exhibition floor!
The Mediso Preclinical User Workshop will be held on Monday from 1pm to 3pm. More details at the EANM 2014 Event Page.
The European Association of Nuclear Medicine (EANM) is the umbrella organisation of nuclear medicine in Europe and represents the sector towards the European Institutions. The EANM 2014 Annual Meeting will be held in Lyon, France this year in October.
WMIS released a call for Late Breaking Abstracts between June 30- July 9, 2014 for the World Molecular Imaging Congress 2014 in Seoul, Korea. The organizers will accept submissions for both oral and poster presentations. To submit your abstract, please visit http://wmis2014.abstractcentral.com/ on or after June 30.
Make sure that you include a Persuasive Data file if you would like your abstract to be considered for an oral presentation. Persuasive data should include figure captions that explain the results of the figure without requiring the reviewer to re-read the main text. Without a Persuasive Data file it is very likely that your submission won't be accepted for oral presentation.
WMIC 2014 Program Emphases are:
- • Chemistry and Imaging Probes: CT, Multimodal, MRI, Nuclear Imaging, Optical Imaging, Photo-Acoustic Imaging, Ultrasound
- • First-in-Human & Clinical Studies: Cardiology, Infectious Disease, Inflammation/Immunology, Metabolic Disease, Neurology, Oncology
- • Preclinical Cell & Tissue Level Studies: Cardiology, Cells, Infectious Disease, Inflammation/Immunology, Neurology, Oncology, Reporter Genes / Signal, Transduction & Epigenetics
- • Preclinical in vivo Studies: Cardiology, Infectious Disease, Inflammation/Immunology, Metabolic Disease, Neurology, Oncology, Reporter Genes / Signal, Transduction & Epigenetics
- • Technology and Software Developments: CT, Clinical PET/SPECT, Hybrid Multimodality, MRI, Optical Imaging, Preclinical PET/SPECT, Photo-Acoustic Imaging, Systems Biology, Ultrasound
VivoQuant™ platform for image viewing and analysis 1.23 was released last week by inviCRO.
The VivoQuant™ application is bundled with our nanoScan small animal in vivo imaging systems and software updates are provided for customers with Mediso USA service contracts. As an Imaging Service contract holder, our users not only have access to service and support, but receive the additional capabilities such us upgrading their InVivoScope or VivoQuant software to the new releases.
VivoQuant 1.23 introduces new and improved features, including:
- New Whole Body Atlas Segmentation Tool,
- Deformable Registration Tool,
- Modeling Operator with GLM and Tracer-kinetic Based Modeling,
- Expanded VivoScript Capabilities with New Example Scripts,
- Upgraded 3D ROI Tool with Enhanced Functionality,
- Improved 3D Image Rendering,
- Integration of the Registration / Reorientation Tool with the 3D ROI Tool,
- Improved MR/CT/PET/SPECT Atlas-based Brain Segmentation Plugin - (Sub-region Volume, Signal, fMRI).
To upgrade your VivoQuant version, please go to Tools|Update Check in the software menu or download directly from the VivoQuant website.
Six white CD-1 mice are scurrying through the litter in their cage, climbing the metal bars, nibbling away at the pellets they are being fed, and snuggling with each other. What they don't yet know is they're about to participate in a pivotal study. One that will save lives - those of mice and, one day, of men. As part of his dissertation, Mathias Kranz, Ph.D. student at the HZDR Research Site Leipzig, is currently investigating the degree of radioactivity that builds up within the bodies of mice whenever radioactive probes - called radiotracers - are used, and identifying in which organs specifically it accumulates. Eventually, these data will be extrapolated to the human magnitude. Radiotracers are chemical compounds that include a radioactive element of some sort, which can help scientists observe metabolic processes in living organisms.
Specifically, in the case of the Leipzig project, we're talking about the two radiotracers [18F]fluspidine and [18F]flubatine - both of them molecules containing the radionuclide 18F (fluorine). They're supposed to ultimately find their way into the diagnostics of cancers and neurodegenerative diseases like Alzheimer's. Key is their ability to imitate properties of various endogenous structures.
Before a radioactive probe is ready for use in the hospital setting, its efficacy and safety must first be documented in living organisms.
Once injected into the human body, they bind with high affinity to certain targets - in the case of the "PET sugar" [18F]FDG, which is also used at the Leipzig site, highly metabolically active tissues like tumors. The emitted radiation from the radioactive molecules can be captured and subsequently analyzed using positron emission tomography (PET). However, before a radioactive tracer can be introduced into the hospital setting, its efficacy and safety to the living organism must first be confirmed. This is a prerequisite imposed by the German Federal Office for Radiation Protection (BfS) and the Federal Institute for Drugs and Medical Devices (BfarM). This multistep procedure starts with work on mice and occasionally pigs and ultimately leads to research conducted on healthy human subjects. Here, the HZDR scientists are receiving support from their colleagues at the Clinic for Nuclear Medicine at Leipzig University Hospital.
Leipzig as reference site
As of spring 2013, when operations by experienced colleagues at the HZDR main site Dresden first commenced, Germany's first-ever commercial full-body PET/MRI for small animals opened in Leipzig - one of only a few worldwide. The HZDR is the reference site for Hungarian manufacturer Mediso (Budapest) - which brings with it a number of obvious benefits: "There are still a handful of delayed-onset childhood illnesses but whenever we do report any problem, help typically arrives within a matter of hours," Mathias Kranz explains. The 27-year-old fellow, who holds a master's in engineering, studied biomedical technology at Ilmenau University of Technology, and has been working at the HZDR Institute of Radiopharmaceutical Cancer Research for about a year now. He is thrilled with the new device: "Not only does it allow us to obtain information about metabolic processes that are happening inside the body, it also yields high-resolution three-dimensional images that document the exact location and distribution of soft tissues." especially when it comes to brain imaging, MR devices yield far better results than conventional PET and computer tomography (CT) combinations.
The mice remain safe
"Without these methods, we would need to dissect the animal subjects, remove individual organs, and then measure them in order to determine the degree of radioactivity that has accumulated in the body following injection of the radiotracer. What's interesting is not only the current dose rate but also how it changes over the course of minutes and hours, which helps determine the organ dose. Thanks to PET/MRI, we're able to conduct even long-term studies using the same exact mouse," Mathias Kranz explains. In the case of other methods, one laboratory animal has to be sacrificed each time a single measurement is obtained.
During examination, the mice are lying on a heated animal bed, their breathing monitored with the help of a pressure sensor. The radioactively labeled substance is injected into the tail vein. The mice are fully anesthetized and won't remember anything afterwards. On a screen, Mathias Kranz is now examining a black and grey image showing the inside of the mouse's body. Red, yellow, and blue spots are lighting up in certain body regions. "Red means these are sites where there is a high degree of radioactivity, in other words that a lot of our substance was deposited in these places," the young scientist explains. At first glance, the liver, kidneys, and bladder are easily recognized - organs, which are actively involved in the substance's elimination from the body.
After the experiments are done, Mathias Kranz calculates the expected effective human dose. This serves as a risk-assessment at the time of introducing the probes into the clinical setting. Based on their results, the researchers have filed for approval of a study with the BfS for use of their newly developed radiotracers (+)-[18F]flubatine and (S)-(-)-[18F]fluspidine in humans. The scientists are working closely with their colleagues at Leipzig University Hospital, Department of Nuclear Medicine, on these projects. The projected start date is early 2014.
A New Spin on the Story of AnyScan
as illustrated by Gergo P.
Lego bricks give the limitless possibilities represented by an unassembled pile. You can build just about anything out of LEGOs these day if you've got the patience and enough bricks.
And this happened with the AnyScan product family of Mediso as Gergo, one of our magnificent physicists (a clear magician in GATE Monte Carlo simulations) created his own slightly greater-than-minifig-scale of the Mediso AnyScan PET-SPECT-CT clinical tomographic scanner.
And the fun part is that the AnyScan S, single-head and dual-head large field-of-view general purpose SPECT camera just received the FDA 510(k) clearance, bringing this great medical device to the US market.
The AnyScan® S is a proven 4th generation system with installations around the world, and offers a unique solution in molecular imaging with an ergonomic open design gantry, variable angle detector positions, small footprint, robust mechanical design with improved safety factor, dual infrared line auto body contouring, total body localizer mode, table design to support patients up to 500 lbs., and pre-programmed robotic gantry motions with full automatic motion positioning and calibration. In addition, the flexible modular system architecture provides a pathway to offer variety of modalities within the AnyScan® family.
Please join us at the Fairmont Copley Plaza in Boston for the second annual Advanced Molecular Imaging and its Clinical Translation course, starting this Sunday, Oct. 27 and continuing through Wednesday, Oct. 30.
Mediso USA is proud to be a sponsor of this important course.
The course will provide a comprehensive overview in the physics, chemistry, engineering, and physiology that are the foundation of molecular imaging. It will cover SPECT, PET, CT, MRI, optical imaging, ultrasound, multi-modality imaging, contrast agent chemistry, radiotracer development, preclinical imaging, issues surrounding clinical translation, and other aspects of molecular imaging.
Course Directors are:
John V. Frangioni, M.D., Ph.D.: Professor of Medicine and Professor of Radiology; Director, Center for Molecular Imaging, Beth Israel Deconess Medical Center, Boston, MA.
Ralph Weissleder, M.D., Ph.D.: Professor of Radiology and Systems Biology; Massachusetts General Hospital, Boston, MA.
Dr. Frangioni's lab includes both a NanoSPECT/CT and a NanoPET/CT small animal imaging system, built by Mediso.
We hope that you are able to attend and that you will visit us at the exhibit hall.
The SNMMI is now accepting abstract submissions for the upcoming SNMMI 2014 Annual Meeting.The congress will be held between June 7-11, 2014 in St. Louis, Missouri.
The abstract submission deadline is Friday, January 3, 2014 (except Technologist Student Submissions). Practically it means that either you will have to write before New Years Eve or you will be willing to work on it right after New Years Eve.
Update: Mediso USA will exhibit at booth #1421 at the SNMMI 2014 Annual Congress. Come and see us!